• Abstract and Figures
• Public Full-text

Special Issue • Medical Devices Lyon Metropolis 2015-2016 BIOTECHFINANCES STRATEGIC INFORMATION FOR BIOTECH DECISION-MAKERS AND INVESTORS “LYON HAS A REAL ACE TO PLAY IN MEDICAL DEVICES” Jacques de Chilly, former MD of Aderly, Greater Lyon’s economic development agency, now heads economic and international development for Lyon Metropolis, with emphasis and ambition on medical devices. BIOTECH FINANCES: Why is strengths in biotechnology, diagnostics Lyon Metropolis strengthening and life sciences. The crossovers with its position in medical devices? medical technology are plentiful. Big Jacques de Chilly: Lyon Metropo- companies value our position and they lis overall strategy in the life sciences are in talks with us about relocating to has until now mainly been focused on and expanding in the Lyon area. In the infectious diseases, neurology and can- past we have already supported dialysis cer. But the changes we have seen in leaders Baxter and Fresenius in their society, especially an aging population, investment plans. Fresenius Group in have led to 6% growth in the medical fact completed three projects in a row, technology sector, outpacing phar- worth €100 M altogether. maceuticals. Medical devices involve crossing boundaries between industry, BF: What are the challenges for academia and research to leverage the years ahead? the necessary skills. Lyon-based busi- JdC: We need to bring in new players, nesses and engineering schools are new investors to the region. It means particularly active in the fields of me- lending further support to the whole of chanics and materials. The medical the life sciences community, through device sector also features in the stra- innovation clusters like Lyonbiopôle tegy of a regional hub made up of local and i-Care Cluster, funding for core and city councils: Lyon Metropolis, facilities like the Accinov platform Saint-Etienne Metropolis, ViennAgglo or the technology research institute and CAPI. Lyon and Saint-Etienne BIOASTER. It also means working in complete each other and combine even closer collaboration with cancer their skills in the mechanics, textiles, research centers, university colleges, plastics and health sectors. and the University of Lyon Foundation. And we mustn’t forget the start-ups BF: And of course the digital which are the small and medium-sized sector... businesses of the future. Our objective Jacques de Chilly JdC: There are indeed crossovers is to coordinate the various city and here on a regional level between the local councils especially for textiles and digital sector and nanotechnologies, medical technology in Saint-Etienne. “The changes we have medical imaging and bioinformatics, Lyon is fortunate in that it lies at the the latter being prominent in Grenoble crossroads of a number of life science seen in society have led to and Lyon. All the technological and capabilities. We really do have an ace industrial elements are available for to play internationally for establishing 6% growth in the medical rolling out a real strategy for medical ourselves firmly in the medical device technology sector.” devices. And this actually plays to our sector and taking the lead. COMPANY TESTIMONIALS INTERVIEWS 1• Michel Thérin, (Medtronic-Covidien) 2 1• David - p 3. 2• Dietrich Wolf, (Eye Tech Care) - 2 4 6 Kimelfeld, p 3. 3• Denys Sournac, (Medicrea) - p 4. (VP Lyon 4• Etienne Binant, (Biom’Up) - p 4. Metropolis) - p 2 5• Elisabeth Ducottet, (Thuasne) - p 5. 1 3 5 2• Emmanuel 6• Emmanuel Blanc, (Edap TMS) - p 5. 1 Blanc, (i-Care Summary Cluster) - p 2 FEATURED ARTICLE ENQUIRIES TO SET UP IN LYON METROPOLIS Florence Agostino-Etchetto, head of the Lyonbiopôle cluster Auvergne-Rhône-Alpes, a unique public/private Jean-Charles Foddis, ecosystem for medical devices in France, pages 6-7 Adriana C. Toma, Nathalie Laurent, (Invest in Lyon) page 8 INTERVIEWS Special Issue • Medical Devices Lyon Metropolis 2015-2016 THE INDUSTRIOUS WINNING STRATEGY OF LYON METROPOLIS David Kimelfeld is the Vice-President of Lyon Metropolis – the authority for the Greater Lyon area – and in charge of economic development. He explains Lyon’s growth strategy for life sciences and medi- cal devices. “Our strategy draws on Lyon’s long-standing medical tradition, on figures like Alain Mérieux, and also on the Lyonbiopôle cluster which has played a pivotal role in shaping the sector and attracting large corpo- rations. Without such a coordinated approach, Sanofi might never have decided to maintain and relocate some of its head offices in Lyon or to invest in its new facility at Neuville-sur-Saône. At the same time the region has witnessed the growth of a number of technology and R&D platforms like the Accinov platform and the BIOASTER Technology Research Institute, all of which contribute to the region’s business appeal. This vibrant hub has also spurred undoubtedly influenced the decisions of German group Fresenius the growth of start-ups like Adocia, Biom’up, Medicrea... and the homeopathy lab Boiron to further invest in their plants in Lyon-Gerland Biodistrict is another core component of our stra- Lyon area. tegy. The investment made in road networks and public areas, Another sign of our high global visibility is the confirmed presence and in an wholly open-air campus with direct connections to the of the International Agency for Research on Cancer (IARC). This city’s main hospitals, has really put Lyon on the map of the Euro- agency is part of the World Health Organization (WHO) and is pean and global healthcare industry. Other areas near Lyon are due to move into new premises within Biodistrict Lyon in 2020. also benefiting from the international strategy. The region’s appeal There is no other agency like it in the world.” “OUR INDUSTRY PLAYERS ARE DEVELOPING REAL HIGH-LEVEL CAPABILITIES” Emmanuel Blanc heads i-Care Cluster, an initiative to federate and support all health technology businesses that design, manufacture and commercialize medical devices and solutions based on health information technology. Here he delivers his expert insight into how the region is positioning itself in this cutting-edge sector. BIOTECH FINANCES: What is special about the regional BF: Do French businesses have critical mass? businesses involved in medical devices? E.B.: This is the big difference with German businesses. French ones Emmanuel Blanc: Lyon is particularly strong in the digital sector, cover an extremely broad range of products, from tubulation to and for electronic patient records. Grenoble has a strong robotics sector ultrasound, but more big names are needed like BioMérieux for in vitro and Saint-Etienne is long tradition in textile innovation. The region is diagnostics, or medium-sized companies like Trixell in Grenoble, or currently experimenting the use of cutting-edge technologies under its Thuasne in Saint-Etienne. New medium-sized companies need to come digital healthcare scheme called Digital Healthcare Territory and led by to the fore, and this is the reason of being of clusters like i-Care. There is the Regional Health Agency. On the world stage too, Auvergne-Rhône- much potential for development in the thousand or so French companies Alpes is shaping up well; it is home to large international groups such as working in medical devices. Medtronic (former Covidien), Fresenius, Baxter and Gambro. BF: What are the challenges for the years ahead? BF: How do regional businesses compare to other European E.B.: The main challenge is financing innovation and streamlining clusters in particular? reimbursements for medical procedures. If we expect to boost the me- E.B.: Auvergne-Rhône-Alpes is mirroring the Paris region which ranks dical technology sector, we’ll have to further develop research and help top for medical devices nationally. But France needs to continue its efforts hospitals invest in innovation and purchase new technology. Our industry as it remains a challenger. We need to redress our trade balance that is in players are developing real high-level capabilities, what we need to do now the red by €800 M in the medical device sector, and ensure our regions is ensure this is leveraged effectively. take a greater market share. We may not be in the same league yet as Lausanne for instance, but we do have the means to substantially raise BF: What do you want to achieve with events like Medica? our game. What will help us here is our healthcare system; industry and E.B.: It’s quite a unique opportunity to reconnect with all the suppliers of business leaders are able to collaborate with clinical teams and labs from medical devices, meet with the main sub-contractors and find new ones. Inserm and CNRS which are particularly skilled in ultrasound and i-Care Cluster uses the event as a way to reach out to similar organizations in medical imaging. If we are able to bring these academic, clinical and in- Germany and Switzerland, thus helping to strengthen our region’s foothold dustrial worlds closer together, then we’ll have a real trump up our sleeve. in the market and to enhance our European and international visibility. 2 BIOTECHFINANCES • 2015-2016 Special Issue • Medical Devices Lyon Metropolis 2015-2016 COMPANY TESTIMONIALS Medtronic-Covidien diversifies into hemostatic gauzes THE INDUSTRIOUS WINNING STRATEGY Michel Thérin, VP R&D of Medtronic-Covidien (Trévoux R&D innovation center) OF LYON METROPOLIS Sofradim Production has which helps stop bleeding during surgical been controlled by the giant operations mainly on the spleen, liver and Medtronic ever since the kidneys. This is a major diversification for a latter took over Covidien of company otherwise known for its parietal which Sofradim had been a subsidiary. reinforcement implants range. Now Sofra- With 85,000 employees, the global leader dim is hoping to establish itself in the hemos- in medical devices has a $27 M turnover. tasis market. Valued at €8 B, it has a 5- 10% “Cross-fertilizating annual growth rate.

Load more

  8

Copy Link